Related Experiment Video
Updated: May 8, 2026
09:13
Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization
1Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, ThailandCentre for Tropical Medicine, Churchill Hospital, Oxford University, Oxford, United Kingdom.
Antimicrobial Agents and Chemotherapy
|September 5, 2013
Summary
Optimizing antimalarial drug dosing is crucial. Early pharmacokinetic-pharmacodynamic (PK-PD) studies can improve dose-finding, ensuring effective treatment and preventing drug resistance in vulnerable populations.
Area of Science:
- Pharmacology
- Infectious Diseases
- Drug Development
Background:
- Antimalarial drugs are often underdosed in endemic areas, particularly for children and pregnant women.
- Suboptimal dosing accelerates antimalarial drug resistance, reducing drug efficacy and lifespan.
- Current dose-finding methods are imprecise, leading to inadequate treatment regimens.
Purpose of the Study:
- To propose an alternative dose-finding strategy for antimalarial drugs.
- To enhance the precision of dosing for improved therapeutic outcomes and resistance management.
- To establish a robust evidence base for antimalarial drug dosage recommendations.
Main Methods:
- Focusing Phase 2 studies on pharmacokinetic-pharmacodynamic (PK-PD) characterization.
- Calibrating in vitro susceptibility data with in vivo observations.
- Utilizing microscopy and quantitative PCR for accurate parasite density assessment.
- Conducting population PK assessments in later trial phases to identify inter-group variations.
Main Results:
- Early characterization of in vivo Minimum Inhibitory Concentration (MIC) provides a basis for dose selection.
- PK-PD modeling allows for accurate quantification of initial therapeutic responses.
- Population PK data informs dose adjustments for diverse age groups and clinical conditions.
Conclusions:
- An integrated PK-PD approach in early-phase studies can optimize antimalarial drug dosing.
- This strategy supports evidence-based dose recommendations for all target populations.
- Improved dosing is essential for effective malaria treatment and combating drug resistance.
Related Concept Videos
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...